Caribou Biosciences, Inc. (CRBU)
| Market Cap | 340.50M |
| Revenue (ttm) | 34.48M |
| Net Income (ttm) | -102.07M |
| Shares Out | 90.32M |
| EPS (ttm) | -1.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,804,094 |
| Open | 3.770 |
| Previous Close | 3.640 |
| Day's Range | 3.690 - 3.900 |
| 52-Week Range | 3.440 - 8.590 |
| Beta | 2.47 |
| Analysts | Strong Buy |
| Price Target | 22.00 (+483.55%) |
| Earnings Date | May 14, 2024 |
About CRBU
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or r... [Read more]
Financial Performance
In 2023, CRBU's revenue was $34.48 million, an increase of 148.91% compared to the previous year's $13.85 million. Losses were -$102.07 million, 2.66% more than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price forecast is $22.0, which is an increase of 483.55% from the latest price.
News
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts h...
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on ...
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safet...
HireRight Holdings Corp. (HRT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)---- $CRBU #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HireRight Holdings Corp. (“HireR...
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-- 30 th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1 st patient dosed in CB-012 AMpLify Phase 1 trial for patie...
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's p...
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
-- Tim Kelly to lead Caribou's technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate piv...
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial continues...
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
-- CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024 -- -- ...
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
-- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clin...
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
-- AMpLify Phase 1 clinical trial to initiate patient enrollment by mid-2024 -- -- CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking to enter the cl...
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment...
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 tria...
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of a...
Caribou Biosciences offers more stock, and shares fall
Shares of Caribou Biosciences Inc. CRBU, +4.90% tumbled 9.7% after hours on Thursday after the biopharma company said it had begun a $100 million share offering. The company, which focuses on genome e...
Caribou's cell therapy shows promise in early-stage cancer study
Caribou Biosciences Inc said on Thursday its experimental CAR T-cell therapy helped clear all signs or decrease tumor size in 94% of patients being treated for a type of cancer in the lymph nodes in a...
Caribou Biosciences Announces Proposed Public Offering of Common Stock
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has commenced...
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate,...
Pfizer makes equity investment in Caribou Biosciences
Pfizer has invested $25 million to buy a minority stake in Caribou Biosciences , making it the latest small biotechnology firm to attract the pharmaceutical giant's interest.
Caribou Biosciences stock soars after Pfizer buys stock priced at a 31% premium
Shares of Caribou Biosciences Inc. CRBU ran up 21.3% toward a three-month high in premarket trading Thursday, after the genome-editing biopharmaceutical company said drug giant Pfizer Inc. has made a ...
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
-- Pfizer purchases $25 million of Caribou common shares -- -- Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou's ...
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Caribou Biosciences, Inc. (NASDAQ: CRBU...
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients at...
Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
-- Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadin...
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
-- CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models -- -- CB-012 IND-enabling studies ongoing; IND submission in r/r AML ...